NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE · Biotechnology · USD

Evommune, Inc. (EVMN) Stock Analysis

Evommune, Inc. (EVMN) is a Biotechnology stock listed on NYSE and quoted in US Dollar.

Last Updated: October 21, 2026

EVMN

$5.17

−$0.21 (−3.90%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare EVMN with… →

EVMN Key Statistics

As of Oct 21, 2026
Trading
Open
$5.41
Previous Close
$5.38
Day's Range
5.13–5.52
52-Week Range
5.09–33.20
Volume
383.38K
Valuation
Market Cap
$187.63M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
18.76
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.68
Financials (FY)
Revenue (FY)
$13.00M
Net Income (FY)
−$68.87M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
36.29M
1-Year Return
−74.44%
Dividend and dates
Earnings Date
November 16, 2026estimated
Avg Volume
680.18K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, EVMN closed at $5.17, −74.44% over 1 year.

Evommune, Inc. (EVMN) has a market capitalization of $187.63M.

EVMN Stock Return by Calendar Year

Evommune, Inc. (EVMN) return since Nov 2025: what $10,000 became

1 year
$10,000 $2,556
−74.44%

If you had invested $10,000 in Evommune, Inc. (EVMN) at the close on November 6, 2025, the earliest close on record here, it would have been worth $2,556 at the close on October 21, 2026: −74.44% in total, −74.44% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−69.80%
2025 (partial year)−15.37%

As of October 21, 2026.

EVMN Valuation vs Biotechnology Median

Median of 608 stocks
MetricEVMNBiotechnology medianvs median
P/S ratio18.7613.3041% above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Evommune, Inc. (EVMN) carries a market capitalisation of $187.63M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 48 employees.

The 52-week range on file runs from $5.09 to $33.20. EVMN last closed at $5.17 on October 21, 2026. That is −$0.21 (−3.90%) against the previous close. The latest close sits 1.57% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $13.00M. The same year closed with a net loss of $68.87M. Earnings per share on a trailing basis come to −3.68.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 18.76 times revenue. On price-to-sales that is 41.09% above the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Daily returns over the trailing 1 year annualize to a volatility of 119.3%. The trailing one-year total return is −74.44%.

Growth & Income

The record shows no dividend for EVMN.

So far in 2026 the total return is −69.80%.

Peer Comparison

Evommune, Inc. (EVMN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Evommune, Inc. EVMN $187.63M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Evommune, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Evommune, Inc.

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.

Visit website →